Tetrahydropyrrolidine compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof
The invention discloses tetrahydropyrrolidine compounds and a preparation method and application thereof, and particularly discloses the tetrahydropyrrolidine compounds shown as the formula (I). Pharmacological tests prove that the tetrahydropyrrolidine compounds have strong inhibitory activity on sphingosine kinase 1 (Sph K1), and some compounds have certain inhibitory effect on tumors. The compounds and medicinal preparations thereof can be used to prepare drugs for treating a series of cancers and inflammatory diseases, such as colon cancer, lung cancer, breast cancer, liver cancer, gastriccancer, lung adenocarcinoma, melanoma and esophageal cancer. The inflammatory diseases include inflammatory bowel disease, hepatitis, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis or multiple sclerosis. The formula (I) is as shown in the specification..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 03. Mai Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Unbestimmt |
|---|
| Beteiligte Personen: |
LIU BO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2019, Last update posted on www.epo.org: 2021-05-03, Last updated: 2021-06-21 |
|---|
| Patentnummer: |
CN110330452 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA005183103 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA005183103 | ||
| 003 | DE-627 | ||
| 005 | 20230503191851.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210529s2021 xx |||||o 00| ||und c | ||
| 035 | |a (DE-627)EPA005183103 | ||
| 035 | |a (EPA)CN110330452 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a und | ||
| 100 | 0 | |a LIU BO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tetrahydropyrrolidine compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2019, Last update posted on www.epo.org: 2021-05-03, Last updated: 2021-06-21 | ||
| 520 | |a The invention discloses tetrahydropyrrolidine compounds and a preparation method and application thereof, and particularly discloses the tetrahydropyrrolidine compounds shown as the formula (I). Pharmacological tests prove that the tetrahydropyrrolidine compounds have strong inhibitory activity on sphingosine kinase 1 (Sph K1), and some compounds have certain inhibitory effect on tumors. The compounds and medicinal preparations thereof can be used to prepare drugs for treating a series of cancers and inflammatory diseases, such as colon cancer, lung cancer, breast cancer, liver cancer, gastriccancer, lung adenocarcinoma, melanoma and esophageal cancer. The inflammatory diseases include inflammatory bowel disease, hepatitis, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis or multiple sclerosis. The formula (I) is as shown in the specification. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds having only nitrogen as ring hetero atom | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a YAO QINGQIANG |e verfasserin |4 aut | |
| 700 | 0 | |a YANG HAORAN |e verfasserin |4 aut | |
| 700 | 0 | |a YAKURA TAKAYUKI |e verfasserin |4 aut | |
| 700 | 0 | |a LI YING |e verfasserin |4 aut | |
| 700 | 0 | |a YU KUN |e verfasserin |4 aut | |
| 700 | 0 | |a CHEN HAIJIAO |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 03. Mai |
| 773 | 1 | 8 | |g year:2021 |g day:03 |g month:05 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/searchResults?DB=EPODOC&locale=en_EP&query=CN110330452A |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2021 |b 03 |c 05 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 03 |c 05 | ||